Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.17  

 
 

NON-COMPETITION AGREEMENT*    
    

        This Non-Competition Agreement ("Agreement") is made this            day
of                        ,            between Intrado Inc.
("Intrado"), by and through its Board of Directors' Compensation Committee, and [Name of Executive] ("Executive"), collectively referred to hereinafter as "the Parties." 

        WHEREAS,
Intrado is in the business of providing emergency communications software, services and systems, including 9-1-1 applications, data management and
network systems that enable the delivery of 9-1-1 calls in the United States of America, along with notification services and other contemplated products and services including
carrier billing software, services and systems, all of which are collectively known as Intrado's "Business;" and 

        WHEREAS,
Executive has served for many years as its [Title(s)] and has diligently served Intrado over the course of his employment with Intrado and its
predecessors; and 

        WHEREAS,
Executive possesses specialized knowledge of Intrado's strategies, products, services, customers, employee skills and other confidential and proprietary trade secret information
accumulated over time at great expense to Intrado, which trade secret information is of value to it and crucial to its business survival, and which provides Intrado with a demonstrable advantage over
competitors; and 

        WHEREAS,
the Parties wish to provide for the terms and conditions by which Executive would receive compensation in exchange for his covenant to not compete with Intrado in the event of a
"Change of Control" of Intrado as defined herein; and 

        WHEREAS,
the Parties agree that this Agreement is in the interest of Intrado and its shareholders. 

        NOW
THEREFORE, the Parties agree as follows: 

        (1)   As
used herein, "Change of Control" means any of the circumstances defined in Intrado's 1998 Stock Incentive Plan as either a "Change of Control" or a "Corporate
Transaction." In the event of a Change of Control of Intrado, the following provisions will apply: 

	(a)
	Except
for termination of employment as a result of Executive's fraudulent conduct or theft involving the assets of Intrado or its affiliated companies, any termination of Executive's
employment with Intrado, for any or no reason, will entitle Executive to the compensation delineated in paragraph 2 below and will also obligate Executive to not compete with Intrado as set
forth in paragraph 3 below.

	(b)
	Executive
may invoke his right to receive the compensation delineated in paragraph 2 below by voluntarily resigning his employment with Intrado. Such a resignation:
(i) must be invoked within one year (365 consecutive days) following the date of the Change of Control, (ii) must be evidenced in writing and must be delivered to Intrado's Board
of Directors not less than fourteen (14) days prior to the effective date of the resignation, and (iii) obligates Executive to not compete with Intrado, as set forth in
paragraph 3 below, as of the effective date of such resignation.

	(c)
	The
termination referenced in subsection 1(a), and the resignation referenced in subsection 1(b), shall each be referred to herein as a "Trigger." If a Trigger is
activated, the compensation amount delineated in paragraph 2 may be taken, in the discretion of Executive, in cash, or as deferred compensation under Intrado's deferred compensation program or
through a third party. Although, under the terms of this Agreement, Executive does not have an express or implied right to elect payment of such compensation in the form of Intrado common stock,
nothing herein shall be deemed to prevent the Parties from discussing and subsequently agreeing to allow Executive to be paid in Intrado common stock so long as such an agreement is by mutual written
agreement. In addition to such compensation, Intrado will provide and pay for, and 

 

Executive
will be entitled to receive, one (1) year of health, retirement and life insurance benefits at the levels in effect for Executive as of the date of the Change of Control under (1)(a),
or as of the date of resignation under (1)(b). 

	(d)
	The
Parties agree that the compensation delineated in paragraph 2 below is reasonable payment in exchange for Executive's covenant to not compete and is therefore not intended
to be subject to application of Section 280G of the Internal Revenue Code ("I.R.C."). In the event a court or agency having competent jurisdiction determines that I.R.C. Section 280G
applies to such compensation, then the following shall apply to this Agreement:

	(i)
	It
is the objective of this Agreement to maximize Executive's Net After-Tax Benefit (as defined below) and give Executive an election to optimize the payment and benefits
to which he is entitled hereunder;

	(ii)
	If
it is determined that any payment or benefit would be subject to the excise tax imposed by I.R.C. Section 4999 or any interest or penalties with respect to such excise tax
(referred to herein as the "Excise Tax"), then Intrado shall first make a calculation under which such payments or benefits are reduced to the extent necessary so that no portion thereof shall be
subject to the Excise Tax (this calculation referred to herein as the "4999 Clawback"). Intrado shall then compare: (a) Executive's Net After-Tax Benefit (as defined below) assuming
application of the 4999 Clawback, with (b) Executive's Net After-Tax Benefit without application of the 4999 Clawback. Executive shall be entitled to elect between (a) and
(b) and shall notify Intrado of such an election within a reasonable time. "Net After-Tax Benefit" means the sum of: (i) all payments and benefits that Executive receives or
is entitled to receive hereunder that would constitute a "parachute payment" within the meaning of Section 280G, less (ii) the amount of Excise Taxes imposed with respect to the payments
and benefits described in (i) above by Section 4999. The determination of whether a payment or benefit is subject to the Excise Tax shall be made by tax counsel selected by Intrado and
reasonably acceptable to Executive. The costs of obtaining the determination shall be paid by Intrado. 

        (2)   If
a Trigger is activated, then within ten (10) days of the date of the Trigger, Intrado or its successor will pay Executive an amount equal to the highest annual
total compensation paid to Executive during the three (3) calendar years preceding the date of the Change of Control, multiplied by    (    ).** Such compensation
calculation shall include salary and bonuses but not equity-based compensation. 

        (3)   If
a Trigger is activated, Executive agrees that, for    (    ) year(s)** from the date of his separation from Intrado as an employee, Executive,
on his/her own behalf, on behalf of any individual, corporation, partnership, or other company, firm, business or organization, will not engage in the activities delineated in
subsections (a) through (e) below in the United States of America or any foreign country where, as of the date of termination (pursuant to paragraph 1(a)) or voluntary
resignation (pursuant to paragraph 1(b)), whichever is applicable, Intrado (i) has existing and paying customers or (ii) has invested a substantial amount of effort or money with
the intent of obtaining paying customers and there is a reasonable probability at the time the Trigger is activated that such Intrado will obtain such customers during the non-competition
period delineated in this paragraph 3 (the "Territory"): 

	(a)
	compete
with Intrado's Business by being associated with the creation, development or sale of products or services which are the same as or substantially the same as to those created,
developed and/or sold by Intrado, its predecessors and/or successors; 

2

 

	(b)
	compete
with Intrado's Business by accepting employment or other remuneration from a competitor of Intrado, its predecessors and/or successors, where such competitor is engaged in
creating, developing and/or selling products or services which are the same or substantially the same as those created, developed and/or sold by Intrado, its predecessors and/or successors;

	(c)
	solicit
the business of any past, present or prospective customer or client of Intrado, its predecessors and/or successors, with respect to Intrado's Business, or interfere or attempt
to interfere with any Business transaction, agreement, and/or relationship in which Intrado, its predecessors and/or successors, was, is or is contemplated to be involved as evidenced by good faith
negotiations or proposals in the drafting stage;

	(d)
	solicit,
recruit or otherwise attempt to persuade any employee, director level or above, to terminate his or her employment with Intrado and/or its successors; and/or

	(e)
	use,
disclose, or otherwise communicate any specialized knowledge or other trade secret of Intrado, its predecessors and/or successors, as defined in Intrado's standard Nondisclosure
Agreement and as referenced in paragraph 4 of this Agreement. 

        (4)   The
Parties agree that the purpose of the non-competition provisions of this Agreement: are designed to protect Intrado's trade secrets and the viability of
Intrado's Business; are valid and enforceable, and, given the nature of Intrado's Business and the knowledge of its Business possessed by Executive, are narrowly drawn and reasonable, including in
scope, duration and the Territory; are necessary for the protection of Intrado's trade secrets as that term is referenced in C.R.S. § 8-2-111(b) (1982, and
any amendments thereto), as defined in C.R.S. § 7-74-102(4) (1986, and any amendments thereto) (the Colorado Uniform Trade Secrets Act), and as delineated in
Intrado's standard Nondisclosure Agreement, incorporated herein by this reference; and apply to executive personnel and officers of Intrado, within the meaning of C.R.S. §
8-2-113(d) (1982, and any amendments thereto). 

        (5)   The
Parties agree that the mutual promises contained herein constitute good and valuable consideration for their entering into this Agreement. 

        (6)   This
Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors, heirs, guardians and personal and legal
representatives, but neither this Agreement nor any rights hereunder may be assigned by Executive without the consent in writing of Intrado and/or its successors. 

        (7)   This
Agreement, including the recitals in its prefatory clauses, represents the complete understanding among the Parties with respect to the subject matter hereof. This
Agreement may not be changed orally and any modifications to it shall not be binding except by a writing signed by the Parties. 

        (8)   The
parties intend that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and the applicable public policies of the State of
Colorado. If any particular portion of this Agreement is adjudicated by a Court of competent jurisdiction to be invalid or unenforceable, such determination shall only apply to that portion of the
Agreement and the remaining 

3

 

covenants
and restrictions shall nevertheless be enforceable to the fullest extent permissible under the laws and public policies applying thereto. 

	
Intrado Inc.
 By and through its Board of Directors' Compensation Committee	
 	

 
	

 	
 	

 
	
 Win Wade, Chairman	 	
 date
	

 	
 	
[Executive]	
 	

 
	
	 	 	 	 
	

 	
 	

 
	
 (signature)	 	
 date

	*
	Intrado
Inc. has entered Non-Competition Agreements with the following executive officers: (1) George Heinrichs, President, Chief Executive Officer, Chairman of the Board and
co-founder; (2) Stephen M. Meer, Chief Technology Officer and co-founder; (3) Lawrence P. Jennings, Chief Operating Officer; (4) Michael D. Dingman, Jr., Chief Financial Officer;
(5) Craig W. Donaldson, Senior Vice President and General Counsel; and (6) Teri L. Depuy, Senior Vice President.

	**
	George
Heinrichs and Stephen M. Meer are entitled to three (3) years of severance pay and must abide by a three (3) year non-compete. Lawrence P. Jennings and Michael D.
Dingman, Jr. are entitled to two (2) years of severance pay and must abide by a two (2) year non-compete. Craig W. Donaldson and Teri L. Depuy are entitled to one (1) year of
severance pay and must abide by a one (1) year non-compete. 

4

QuickLinks

NON-COMPETITION AGREEMENTExhibit 10.21

 

NOTE:  Portions of this
Exhibit are the subject of a Confidential Treatment Request by the Registrant
to the Securities and Exchange Commission (the “Commission”).  Such portions have been redacted and are
marked with a “[***]” in place of the redacted language.  The redacted information has been filed
separately with the Commission.

 

 

THIRD AMENDMENT TO

LICENSE AGREEMENT

 

                This is the
Third Amendment to the License Agreement (the “Agreement”) between Sangamo
BioSciences, Inc. (“Sangamo”) and Baxter Healthcare Corporation (“Baxter”),
dated January 11, 2000.  This Third
Amendment shall be effective as of August 14, 2003.

RECITALS

 

                WHEREAS, the Agreement
was assigned by Baxter to Edwards Lifesciences LLC (“Edwards”) pursuant to a
Reorganization Agreement between Baxter International Inc. and Edwards
Lifesciences Corporation dated March 31, 2000;

 

                WHEREAS,
a First Amendment to the License Agreement (“First Amendment”) was entered into
by Sangamo and Edwards effective October 16, 2001; and

WHEREAS, a Second
Amendment to the License Agreement (“Second Amendment”) was entered into by
Sangamo and Edwards effective November 14, 2002.

 

                NOW,
THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Agreement is hereby amended as
follows:

 

1.             Delete paragraph
4.2.2 from the Second Amendment to the License Agreement and insert the
following new paragraph 4.2.2:

                4.2.2  Within thirty (30) days of the first achievement of each of the
following research and development milestones, EDWARDS shall pay to SANGAMO the
following milestone payments:

 

 

                (a)           One
million four hundred thousand dollars ($1,400,000) upon delivery to EDWARDS by
SANGAMO of data satisfactory to both Parties demonstrating the development of a
lead ZFP therapeutic product candidate and supporting pre-clinical data in a
therapeutically-relevant angiogenesis animal model;

 

                (b)           Fifty thousand dollars
($50,000) upon completion and delivery of the items specified in Paragraph
5.1(b) as more specifically set out in the Second Amended Schedule 2 attached
hereto, and demonstration of efficacy in a pivotal animal study.  This study is to be defined after the pilot
study data analysis and consultation with the FDA;

 

                (c)           Fifty Thousand Dollars ($50,000) upon completion and
delivery of the items specified in Schedule 3 attached hereto;

 

                (d)           Four Hundred Thousand Dollars
($400,000) upon the completion and delivery to EDWARDS of the research vector
constructs (other than the VOP32E clinical construct) developed by SANGAMO,
together with the associated cloning designs and vector map reports, provided
that such payment shall be due no earlier than January 15, 2004.

 

2.  Delete Amended Schedule 2
and insert the attached Second Amended Schedule 2.

 

3.             The Agreement, as amended in the First Amendment, the
Second Amendment  and this Third
Amendment, together with the Research Funding Agreement between SANGAMO and
EDWARDS dated January 11, 2000, as amended in the First Amendment thereto,
represent the entire agreement between the parties with respect to its subject
matter and supersede all prior agreements and understandings between the
parties.

 

2

 

 

4.             All other terms and conditions shall remain the same.

 

	
  EDWARDS LIFESCIENCES LLC

  	
   

  	
  SANGAMO BIOSCIENCES, INC.

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Name:

  	
   

  	
   

  	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title:

  	
   

  	
   

  	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
   

  	
   

  	
   

  	
  Date:

  	
   

  	
   

  

 

3

 

Second Amended Schedule 2 to
License Agreement

(Exhibit B to
Research Funding Agreement)

 

Development
of  *** and *** lots for preclinical use
containing a ZFP transgene construct which upregulates VEGF-A in humans.

 

Q1-Q4 2003 (Sangamo specific activities and costs)

 

1.               *** data analysis from animal
studies through the pivotal animal study with a target turnaround of two weeks.

 

2.               Finalized reports on ***.  The format and content is flexible but in
sufficient detail and quality to be referenced in IND filings.

 

3.               Animal study reports from the
studies performed through Q1 2003.  The
format and content is flexible but in sufficient detail and quality to be
referenced in IND filings.

 

4.               Storage and formulation of *** and ***
as needed to support animal studies through pivotal animal study.

 

5.               Technology/materials
transfer to GMP analytical and manufacturing facility to
produce, test, and qualify investigational product. No GMP analytical
validation or manufacturing need take place at Sangamo.

 

*** Certain
information on this page has been omitted and filed separately with the
Commission pursuant to a request for Confidential Treatment.

 

 

4

 

Schedule 3 to License Agreement

(Exhibit C to Research Funding Agreement)

 

Development of *** and *** lots for preclinical use
containing a ZFP transgene construct which down-regulates Phospholamban (PLN)
by ZFPs in cell models.

 

Q1 2003 (Sangamo specific activities and costs)

 

1. Progress report of ZFP development which may
include design considerations, candidate ZFPs, gene assay development, cell
screening, and Dnase1 accessibility mapping.

 

2.  Sequence
definition report describing the mapping of the transcription
initiation sites, locus cloning, sequencing, and sequence alignment across ***.

 

Q2-Q4 2003 (Sangamo specific activities and costs)

 

1.              Report on ZFP cell screening
and optimization of hits.  

 

2.               *** analysis report with the ***
on two cell lines (to be agreed upon) showing sufficient specificity.

 

3.               Activity report of PLN showing
down-regulation of PLN in cell culture using two cell lines (to be agreed
upon).

 

4.               Master research banks for *** and
control transgene (bgal-GFP) make both viral vector and plasmid constructs —
for each supply a narrative on the method of construction, map, and sequences
of transgene, testing and qualification (non-GLP), and 20 vials for each bank.

 

5.               Lots for early animal
testing for *** and control transgene (bgal-GFP) make two
lots of both *** and *** constructs — ***.

 

6.               *** development report describing
methods and supporting data for analysis of PLN *** in cell culture and animal
tissue (mouse, rat, rabbit, and/or pig). 
This will include sufficient detail to be able to duplicate the
procedure including ***, controls, and specific methodology.

 

*** Certain
information on this page has been omitted and filed separately with the
Commission pursuant to a request for Confidential Treatment.

 

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00064-of-00352.parquet"}]]